GeoVax Labs, Inc. (NASDAQ:GOVX – Get Rating) shares traded down 3.3% on Tuesday . The company traded as low as $0.68 and last traded at $0.70. 400,320 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 559,643 shares. The stock had previously closed at $0.72.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of GeoVax Labs in a report on Wednesday, October 26th. They issued a “buy” rating and a $8.00 price objective for the company. Maxim Group lowered their price objective on shares of GeoVax Labs to $3.00 in a report on Tuesday, November 15th.
GeoVax Labs Trading Down 3.3 %
The stock’s fifty day moving average is $0.70 and its 200 day moving average is $1.13. The company has a market capitalization of $18.40 million, a P/E ratio of -0.24 and a beta of 2.80.
Institutional Investors Weigh In On GeoVax Labs
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in GeoVax Labs by 160.3% in the 3rd quarter. Renaissance Technologies LLC now owns 1,045,526 shares of the company’s stock worth $1,140,000 after purchasing an additional 643,897 shares in the last quarter. BlackRock Inc. raised its holdings in GeoVax Labs by 104,042.1% in the 3rd quarter. BlackRock Inc. now owns 413,444 shares of the company’s stock worth $451,000 after purchasing an additional 413,047 shares in the last quarter. Hidden Lake Asset Management LP bought a new position in GeoVax Labs in the 3rd quarter worth $366,000. Vanguard Group Inc. raised its holdings in GeoVax Labs by 112.5% in the 3rd quarter. Vanguard Group Inc. now owns 549,966 shares of the company’s stock worth $600,000 after purchasing an additional 291,200 shares in the last quarter. Finally, State Street Corp raised its holdings in GeoVax Labs by 659.4% in the 3rd quarter. State Street Corp now owns 168,142 shares of the company’s stock worth $183,000 after purchasing an additional 146,000 shares in the last quarter. 11.82% of the stock is currently owned by institutional investors.
About GeoVax Labs
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
- Get a free copy of the StockNews.com research report on GeoVax Labs (GOVX)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.